Journal article
Modified Vaccinia Virus Ankara Encoding Influenza Virus Hemagglutinin Induces Heterosubtypic Immunity in Macaques
Nicholas W Florek, Jason T Weinfurter, Sinthujan Jegaskanda, Joseph N Brewoo, Tim D Powell, Ginger R Young, Subash C Das, Masato Hatta, Karl W Broman, Olav Hungnes, Susanne G Dudman, Yoshihiro Kawaoka, Stephen J Kent, Dan T Stinchcomb, Jorge E Osorio, Thomas C Friedrich
Journal of Virology | AMER SOC MICROBIOLOGY | Published : 2014
DOI: 10.1128/JVI.01219-14
Abstract
UNLABELLED: Current influenza virus vaccines primarily aim to induce neutralizing antibodies (NAbs). Modified vaccinia virus Ankara (MVA) is a safe and well-characterized vector for inducing both antibody and cellular immunity. We evaluated the immunogenicity and protective efficacy of MVA encoding influenza virus hemagglutinin (HA) and/or nucleoprotein (NP) in cynomolgus macaques. Animals were given 2 doses of MVA-based vaccines 4 weeks apart and were challenged with a 2009 pandemic H1N1 isolate (H1N1pdm) 8 weeks after the last vaccination. MVA-based vaccines encoding HA induced potent serum antibody responses against homologous H1 or H5 HAs but did not stimulate strong T cell responses pri..
View full abstractGrants
Awarded by NIH
Awarded by NIH National Research Service Award
Awarded by NIH Research Facilities Improvement Program
Awarded by NATIONAL CENTER FOR RESEARCH RESOURCES
Awarded by NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES
Awarded by OFFICE OF THE DIRECTOR, NATIONAL INSTITUTES OF HEALTH
Funding Acknowledgements
This work was supported by a supplement to the WNPRC base grant (NIH P51 RR000167/OD011106), awarded to T.C.F., and by a donation to the University of Wisconsin School of Veterinary Medicine from Inviragen, Inc. N.W.F. was supported by NIH National Research Service Award T32 GM07215. This research was conducted in part at a facility constructed with support from NIH Research Facilities Improvement Program grants RR015459 and RR020141.